Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.
Inhibrx's cancer drug showed promise in early testing, so they're testing it with more patients to see if it keeps working well. When a medicine company gets good early results, it's a sign they believe in the drug—but we still have to wait for bigger tests to know if it will actually help patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.